search
Back to results

Fontan-Sprechstunde

Primary Purpose

Univentricular Heart

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Univentricular Hearts
Sponsored by
University of Erlangen-Nürnberg Medical School
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Univentricular Heart

Eligibility Criteria

6 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • congenital heart defect of the univentricular type that has led to Fontan circulation

Exclusion Criteria:

  • no exclusion criteria

Sites / Locations

  • UniversitätsklinikumRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

TCPC completed

Arm Description

All patients after TCPC completion

Outcomes

Primary Outcome Measures

Reducing mortality and morbidity and improving quality of life in long-term care for Fontan patients
Fontan Tunnel Obstruction Fontan-typical klin. Symp. defined in points 5.+6. o. Presence of edema, ascites, susceptibility to infections, reduced resilience, cyanosis, lack of size and weight development, diarrhea Heart or heart valve insufficiency defined as end-diastolic volume/BSA (EDP corrected) above the norm, ventricle ejection fraction (EF) <50%, atrioventricular heart valve insufficiency (AVI) >grade 2, aortic valve insufficiency >grade 2 Pathological lymphatic vessel imaging defined as lymphatic vasodilation (LAE) type ≥ 3 according to Biko et al. (abnormal supraclavicular lymphatic vasodilation with infiltration of the mediastinum) (7). Presence of mesenteric lymphatic vascular congestion (8) Hypoproteinaemia defined as serum albumin <3.4 mg/dl (4), total protein (TP) <50 g/l protein-losing enteropathy (PLE) defined as (3, 4) Failing Fontan defined as Operative Fontan Take-down, Listing for Heart Transplantation and/or Death

Secondary Outcome Measures

Full Information

First Posted
September 21, 2022
Last Updated
September 28, 2022
Sponsor
University of Erlangen-Nürnberg Medical School
search

1. Study Identification

Unique Protocol Identification Number
NCT05563376
Brief Title
Fontan-Sprechstunde
Official Title
Prospektive Erfassung Von standardmäßig Erhobenen Daten im Rahmen Der Erlanger Fontan-Sprechstunde Zur Behandlung Und Überwachung Von PatientInnen Mit univentrikulärem Herzfehler im Sinne Einer Fontan-Zirkulation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
September 1, 2031 (Anticipated)
Study Completion Date
September 1, 2041 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Erlangen-Nürnberg Medical School

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias. The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.
Detailed Description
In particular, the following points will be scientifically analyzed: The development of lymphatic drainage disorders (7-9) The cellular changes of the immunological system and metabolome (10) In addition to the clinical routine, weight-adapted EDTA blood for the isolation of peripheral blood mononuclear cells (PBMCs) for the scientific investigation of immunological changes and serum for the analysis of the metabolome will be examined at three times (Figure 1: Times 2, 4, 7) as part of a routine blood sample (10). The recording and treatment of psychological, social and developmental abnormalities with the help of standardized questionnaires. The evaluation of special sonography examinations of the liver and kidney in the long-term course, as well as their treatment. The assessment of the hemodynamic peculiarities and the classification with regard to Cardiac function in the long-term course of patients with Fontan circulation. The assessment of various laboratory parameters as risk parameters for the development of complications. The recording of cardiopulmonary performance in the long-term course and its ability to be influenced by education regarding sporting activity and the handing over of an individualized training plan. The influence of physical activity on possible complications of Fontan circulation. The influence of early psychological, nutritional, or social intervention in the event of abnormalities on later complications of Fontan circulation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Univentricular Heart

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TCPC completed
Arm Type
Other
Arm Description
All patients after TCPC completion
Intervention Type
Diagnostic Test
Intervention Name(s)
Univentricular Hearts
Intervention Description
Prevention when factors are recognized
Primary Outcome Measure Information:
Title
Reducing mortality and morbidity and improving quality of life in long-term care for Fontan patients
Description
Fontan Tunnel Obstruction Fontan-typical klin. Symp. defined in points 5.+6. o. Presence of edema, ascites, susceptibility to infections, reduced resilience, cyanosis, lack of size and weight development, diarrhea Heart or heart valve insufficiency defined as end-diastolic volume/BSA (EDP corrected) above the norm, ventricle ejection fraction (EF) <50%, atrioventricular heart valve insufficiency (AVI) >grade 2, aortic valve insufficiency >grade 2 Pathological lymphatic vessel imaging defined as lymphatic vasodilation (LAE) type ≥ 3 according to Biko et al. (abnormal supraclavicular lymphatic vasodilation with infiltration of the mediastinum) (7). Presence of mesenteric lymphatic vascular congestion (8) Hypoproteinaemia defined as serum albumin <3.4 mg/dl (4), total protein (TP) <50 g/l protein-losing enteropathy (PLE) defined as (3, 4) Failing Fontan defined as Operative Fontan Take-down, Listing for Heart Transplantation and/or Death
Time Frame
50 Jahre

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: congenital heart defect of the univentricular type that has led to Fontan circulation Exclusion Criteria: no exclusion criteria
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Isabelle Schöffl, PD
Phone
09131 85 33750
Email
isabelle.schoeffl@uk-erlangen.de
First Name & Middle Initial & Last Name or Official Title & Degree
Sven Dittrich, Prof.
Phone
09131 85 33750
Email
sven.dittrich@uk-erlangen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sven Dittrich, Prof.
Organizational Affiliation
Universitätsklinikum Erlangen
Official's Role
Study Chair
Facility Information:
Facility Name
Universitätsklinikum
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sven Dittrich, Prof.
Phone
09131 85 33750
Email
sven.dittrich@uk-erlangen.de
First Name & Middle Initial & Last Name & Degree
Isabelle Schöffl, PD
Phone
09131 85 33750
Email
isabelle.schoeffl@uk-erlangen.de

12. IPD Sharing Statement

Learn more about this trial

Fontan-Sprechstunde

We'll reach out to this number within 24 hrs